Jagsonpal Pharmaceuticals to acquire 85% of Aequitas Healthcare for Rs 20.8 crore

What Jagsonpal Pharmaceuticals announced

Jagsonpal Pharmaceuticals Ltd filed a press release on 29 June 2026 with the Bombay Stock Exchange and the National Stock Exchange, stating that it has entered into a definitive agreement to acquire an 85 percent equity stake in Aequitas Healthcare Private Limited. The deal represents Jagsonpal’s first foray into the hospital‑distribution segment of the Indian pharmaceutical market and aligns with its long‑term vision of expanding an omnichannel specialty‑healthcare footprint.

Details of the acquisition

Aequitas Healthcare, incorporated in 2017 and headquartered in Mumbai, focuses on the sale and distribution of pharmaceutical products to hospitals. The company reported revenue of Rs 53 crore for the financial year 2026, reflecting a solid presence across major hospital chains in the country. Under the terms of the agreement, Jagsonpal will acquire 85 percent of Aequitas’ equity for a total consideration of Rs 20.8 crore. The remaining 15 percent will be retained by the current directors of Aequitas, who will continue to be involved in the business post‑transaction.

Transaction terms and timeline

The acquisition price will be funded entirely from Jagsonpal’s internal accruals, meaning no external debt or equity dilution is expected as a result of the deal. The agreement is subject to the usual closing conditions, including regulatory approvals and shareholder consents. Both parties anticipate that the transaction will be concluded by 15 July 2026.

Legal counsel for Jagsonpal was provided by J Sagar & Associates, while Noverra Partners advised Aequitas on the transaction. The press release quoted senior executives from both companies, highlighting the strategic fit: Jagsonpal’s established brand portfolio in gynecology, orthopaedics and dermatology is expected to benefit from Aequitas’ strong institutional relationships, while Aequitas’ leadership sees the partnership as a catalyst for the next phase of growth.

Key facts at a glance

Why this matters for investors

The acquisition expands Jagsonpal’s addressable market beyond its traditional retail prescription channel into hospital‑based distribution, a segment that currently accounts for roughly 10 percent of total pharmaceutical sales in India and is growing faster than the overall market. By securing a majority stake in a company that already serves leading hospital chains, Jagsonpal gains immediate access to an established distribution network without the time and cost of building one from scratch.

Because the purchase is financed from internal accruals, the deal does not entail new debt issuance or equity dilution, preserving the company’s current capital structure. However, investors should monitor the integration process, as the success of the strategic pivot will depend on how effectively Jagsonpal can leverage Aequitas’ relationships and align its product portfolio with hospital procurement requirements.

Regulatory approvals and the satisfaction of customary closing conditions remain pending. Until those conditions are met, the transaction is not final, and any material change in the terms could affect the anticipated benefits.

Conclusion

Jagsonpal Pharmaceuticals has signed a definitive agreement to acquire an 85 percent stake in Aequitas Healthcare for Rs 20.8 crore, funded from internal accruals. The deal, expected to close by mid‑July 2026, provides Jagsonpal with a ready platform in the hospital distribution segment while allowing Aequitas’ existing directors to retain a minority interest. Completion of customary closing conditions will determine when the strategic advantages outlined by management become operational.